Compiled all in one place, read news articles from each of the news categories, about drugs, the pharmaceutical industry, national and international awareness causes, scientific meetings, trending stories and epgonline.org headlines.

Site News

Added 1 day ago Drug news

Phase III INVICTUS study results positive for ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors.-Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals, Inc. announced positive top-line data from the INVICTUS pivotal Phase III clinical study of ripretinib, a broad-spectrum KIT...

Added 2 days ago Drug news

FDA approves Inrebic to treat primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.- Celgene

Celgene Corporation announced the FDA has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary...

Added 2 days ago Drug news

EMA accepts MAA for filgotinib to treat rheumatoid arthritis .- Gilead Sciences + Galapagos NV

Gilead Sciences, Inc. and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib , an investigational, oral, selective...

Added 2 days ago Drug news

FDA approves Rozlytrek to treat ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors- Genentech/Roche

Genentech has announced that the FDA has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell...

Added 2 days ago Drug news

FDA approves Rinvoq to treat moderately to severely active rheumatoid arthritis . AbbVie.

AbbVie has announced that the FDA has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for...

Added 2 days ago Drug news

FDA approves Wakix for excessive daytime sleepiness in narcolepsy.- Harmony Biosciences

The FDA has approved Wakix (pitolisant), from Harmony Biosciences, for the treatment of excessive daytime sleepiness (EDS) in adult patients...

Added 2 days ago Drug news

Leo Pharma A/S acquires rights to develop and market Kyntheum for moderate-to-severe psoriasis outside of Europe.

Leo Pharma A/S, a global leader in medical dermatology, has announced it has acquired the exclusive rights to develop and...

Added 3 days ago Drug news

Novan’s phase III Molluscum pivotal program completes enrollment of B-SIMPLE trials for SB 206.

Novan, Inc. announced that the Company has recently completed patient recruitment in the Company’s ongoing “B-SIMPLE” (Berdazimer Sodium In Molluscum...

Added 3 days ago Drug news

Mallinckrodt announces positive top-line results from its pivotal phase III CONFIRM trial of terlipressin in patients with hepatorenal syndrome Type 1.

Mallinckrodt Plc announced positive top-line results from its pivotal Phase III CONFIRM clinical study evaluating the efficacy and safety of...

Search all news articles